Apellis Pharmaceuticals Inc - Company Profile
Powered by 
All the sales intelligence you need on Apellis Pharmaceuticals Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Apellis Pharmaceuticals Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Apellis Pharmaceuticals Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
View up-to-date information on Apellis Pharmaceuticals Inc patents, including inventor and filing insights.
Patent Trends
| Publication Identifier | Document Type | Title | Classification-CPC | Publication Date |
|---|---|---|---|---|
| US20230381269A1 | Application | Methods of treating eye disorders | A61K38/12; A61K47/26; A61K9/0019; A61K9/0048; A61P27/02 | November 30, 2023 |
| WO2023129496A3 | Application | Rnas for complement inhibition | C12N15/113; C12N2310/14; C12N2310/315; C12N2310/321; C12N2310/322; C12N2310/344; A61K31/712 | November 02, 2023 |
| EP4259187A1 | Application | Genomeditierung von komplement | C12N15/113; C12N2310/20; C12N9/22; C12N9/78; A61K38/00; C07K2319/00 | October 18, 2023 |
| WO2022251484A9 | Search Report | Treatment of complement-mediated disorders | C12N15/113; C12N2310/14; C12N2310/315; C12N2310/343; C12N2310/351; C12N2320/11; C12N2320/32; A61K31/713; A61K38/12; A61P27/02 | October 12, 2023 |
| US20230302038A1 | Application | Rnas for complement inhibition | C12N15/113; C12N15/86; C12N2310/14; C12N2310/141; C12N2320/31; C12N2330/51; C12N2750/14143; C12N2750/14145; A61K31/713; A61P43/00; C07K16/18 | September 28, 2023 |
Top Inventors by Filings (Count by publication)
| Name | Count |
|---|
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer